Publication:
Effects of cigarette smoking on quinine pharmacokinetics in malaria

dc.contributor.authorS. Pukrittayakameeen_US
dc.contributor.authorP. Pitisuttithumen_US
dc.contributor.authorH. Zhangen_US
dc.contributor.authorA. Jantraen_US
dc.contributor.authorS. Wanwimolruken_US
dc.contributor.authorN. Whiteen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherJohn Radcliffe Hospitalen_US
dc.contributor.otherUniversity of Otagoen_US
dc.contributor.otherWestern University of Health Sciencesen_US
dc.date.accessioned2018-07-24T03:05:17Z
dc.date.available2018-07-24T03:05:17Z
dc.date.issued2002-09-17en_US
dc.description.abstractObjective: Quinine is an important antimalarial drug that is metabolised mainly by the hepatic mixed-function microsomal enzyme cytochrome P450. Cigarette smoking in healthy volunteers has been reported to enhance quinine clearance. The present study evaluated the effects of smoking on quinine pharmacokinetics in patients with uncomplicated falciparum malaria treated with a 7-day course of oral quinine. Of 22 studied male patients, 10 were regular smokers and 12 were non-smokers. Methods: All patients were treated with a 7-day oral regimen of quinine sulfate (10 mg salt/kg three times a day). Serial venous blood samples were taken for quinine levels before and during treatment at 12 h and 24 h and then daily until day 7. Plasma quinine and 3-hydroxyquinine concentrations were assayed using high-performance liquid chromatography. Quinine pharmacokinetics were evaluated using non-compartmental modelling. Results: All patients recovered, and there were no significant differences in clinical responses or cure rates between the two studied groups (P ≥ 0.32). The median (range) fever clearance time was 51 h (4-152 h) and mean (SD) parasite clearance time was 74 ± 28 h. The overall median times to maximum concentrations of quinine and its main metabolite 3-hydroxyquinine were 1.5 days and 4.0 days, respectively. The maximum concentrations of quinine were approximately tenfold higher than 3-hydroxyquinine. There were no significant differences in any pharmacokinetic variables for the parent compound or metabolite between the two groups. The median area under the plasma drug concentration- time curve to day 7 (AUC0-7) of quinine in non-smokers was 67.0 μg/ml/day and in smokers was 51.3 μg/ml/day, and AUC0-7values of 3-hydroxyquinine were 6.2 μg/ml/day and 4.8 μg/ml/day, respectively. Conclusion: These results indicated that cigarette smoking has no significant effects on quinine pharmacokinetics or the therapeutic response in patients with falciparum malaria.en_US
dc.identifier.citationEuropean Journal of Clinical Pharmacology. Vol.58, No.5 (2002), 315-319en_US
dc.identifier.doi10.1007/s00228-002-0447-4en_US
dc.identifier.issn00316970en_US
dc.identifier.other2-s2.0-0036373702en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/20357
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0036373702&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleEffects of cigarette smoking on quinine pharmacokinetics in malariaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0036373702&origin=inwarden_US

Files

Collections